ストックスクリーナーアプリを入手
1.375
1.48%
0.025
前日終値:
$1.35
開ける：
$1.34
24時間の取引高:
110.74K
Relative Volume:
0.09
時価総額：
$85.61M
収益：
-
当期純損益:
$-73.79M
株価収益率:
-0.7473
EPS:
-1.84
ネットキャッシュフロー:
$-77.44M
1週間 パフォーマンス:
-9.27%
1か月 パフォーマンス:
-27.13%
6か月 パフォーマンス:
+28.04%
1年 パフォーマンス:
+5.38%
1日の値動き範囲:
$1.305
$1.385
1週間の範囲:
$1.28
$1.55
52週間の値動き範囲:
$0.8332
$5.55
Pyxis Oncology Inc Stock (PYXS) Company Profile
Compare PYXS vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
1.375 | 84.06M | 0 | -73.79M | -77.44M | -1.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.58 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.23 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
836.88 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.07 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
349.91 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-03 | 再開されました | Stifel | Buy |
| 2025-09-04 | 開始されました | Guggenheim | Buy |
| 2024-11-21 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2024-11-08 | 開始されました | Stephens | Overweight |
| 2024-08-08 | 開始されました | Stifel | Buy |
| 2024-05-07 | 再開されました | Jefferies | Buy |
| 2024-02-09 | 開始されました | BTIG Research | Buy |
| 2024-01-23 | 開始されました | Leerink Partners | Outperform |
| 2023-09-05 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-11-02 | 開始されました | BofA Securities | Neutral |
| 2021-11-02 | 開始されました | Credit Suisse | Outperform |
| 2021-11-02 | 開始されました | Jefferies | Buy |
すべてを表示
Pyxis Oncology Inc (PYXS) 最新ニュース
Pyxis Oncology Announces Interim CEO Amid Leadership Transition - TipRanks
Pyxis Oncology (PYXS) taps board member Thomas Civik as interim CEO in leadership shift - Stock Titan
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Pyxis Oncology (PYXS) - The Globe and Mail
Pyxis Oncology appoints Thomas Civik as interim CEO By Investing.com - Investing.com Nigeria
Pyxis Oncology, Inc. Announces Chief Executive Officer Changes, Effective February 3, 2026 - marketscreener.com
Pyxis Oncology names Thomas Civik as interim CEO - marketscreener.com
Pyxis Oncology Appoints Thomas Civik as Interim CEO - citybiz
Pyxis Oncology appoints Thomas Civik as interim CEO - Investing.com
Pyxis Oncology Announces Interim CEO Appointment and - GlobeNewswire
Pyxis Oncology, Inc. (NASDAQ:PYXS) Short Interest Update - MarketBeat
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Pyxis Oncology (NASDAQ:PYXS) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Pyxis Oncology (NASDAQ:PYXS) Downgraded by Wall Street Zen to “Sell” - Defense World
Wall Street Zen Upgrades Pyxis Oncology (NASDAQ:PYXS) to “Hold” - Defense World
Wall Street Zen Upgrades Pyxis Oncology (NASDAQ:PYXS) to "Hold" - MarketBeat
Cancer drug developer Pyxis Oncology to join 2 November investor chats - Stock Titan
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff - The Spec
Pyxis Oncology Reports Increased Losses Amid Development Focus - MSN
Returns Recap: How Pyxis Oncology Inc. stock compares to growth peers2025 Fundamental Recap & Low Volatility Stock Recommendations - ulpravda.ru
Aug Action: Will Pyxis Oncology Inc. stock benefit from automationPortfolio Value Report & Precise Swing Trade Alerts - ulpravda.ru
Will Pyxis Oncology Inc. stock benefit from automationJuly 2025 Decliners & Consistent Income Trade Ideas - Улправда
Will Pyxis Oncology Inc. stock gain from government policiesJuly 2025 Final Week & Fast Entry Momentum Trade Alerts - Улправда
Is Pyxis Oncology Inc. stock a dividend growth opportunity2025 Key Lessons & Real-Time Chart Pattern Alerts - Улправда
The $537B Precision Pivot: Why Molecular Monitoring is the New Oncology Standard - The Globe and Mail
After-Hours Gainers: ALXO, GMED, ACRV, And Biotech Peers Rally On Trial Data And Earnings Updates - RTTNews
Pyxis Oncology, Inc.Common Stock (NQ: PYXS - FinancialContent
Is Pyxis Oncology Inc. stock recession proofHead and Shoulders Patterns & Create Your Free Watchlist Instantly - ulpravda.ru
PYXS Stock Price, Forecast & Analysis | PYXIS ONCOLOGY INC (NASDAQ:PYXS) - Chartmill
Pyxis Oncology (NASDAQ:PYXS) versus Kiora Pharmaceuticals (NASDAQ:KPRX) Head to Head Contrast - Defense World
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
PYXS,RPTX Dividends - Finviz
Goosehead Insurance Inc 2OX Stock Analysis and ForecastMomentum Trading Signals & Exceptional Return Capital - earlytimes.in
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Is Pyxis Oncology Inc. stock positioned well for digital economyShort-Term Trading Alerts & Easy Tools to Analyze Your Investment Risk - bollywoodhelpline.com
Pyxis Oncology Inc. (PYXS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Short Interest in Pyxis Oncology, Inc. (NASDAQ:PYXS) Drops By 57.3% - MarketBeat
Pyxis Oncology Stock Plunge: A Buy Signal? - StocksToTrade
Pyxis Oncology Stock Slides 73% With A 7-Day Losing Spree - Trefis
Would You Still Hold Pyxis Oncology Stock If It Fell Another 30%? - Trefis
Bear Alert: Is Pyxis Oncology Inc. stock a contrarian buy2025 Year in Review & Safe Entry Momentum Stock Tips - Улправда
How Pyxis Oncology Inc. stock compares to growth peersQuarterly Profit Summary & Weekly High Conviction Trade Ideas - Улправда
Pyxis Oncology Stock 6-Day Losing Spree: Stock Falls 71% - Trefis
Pyxis Oncology (NASDAQ:PYXS) Lowered to Sell Rating by Wall Street Zen - MarketBeat
HC Wainwright & Co. Maintains Pyxis Oncology (PYXS) Buy Recommendation - Nasdaq
RBC Capital Maintains Pyxis Oncology (PYXS) Outperform Recommendation - Nasdaq
Pyxis Oncology price target lowered to $5 from $8 at RBC Capital - MSN
Pyxis Oncology sees cash runway into 4Q26 - MSN
Pyxis Oncology stock price target raised to $7 by H.C. Wainwright - Investing.com Nigeria
RBC Capital Lowers Price Target for Pyxis Oncology (PYXS) to $5, Maintains Outperform Rating | PYXS Stock News - GuruFocus
Analysts Sound Alarm On Pyxis Oncology's Tiny Trial - Benzinga
Pyxis Oncology Inc (PYXS) 財務データ
収益
当期純利益
現金流量
EPS
0.36%
2.08%
大文字化:
|
ボリューム (24 時間):